248 related articles for article (PubMed ID: 20668427)
1. Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients.
Ford BA; Eby CS; Scott MG; Coyne DW
Kidney Int; 2010 Oct; 78(8):769-73. PubMed ID: 20668427
[TBL] [Abstract][Full Text] [Related]
2. Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA.
Peters HP; Rumjon A; Bansal SS; Laarakkers CM; van den Brand JA; Sarafidis P; Musto R; Malyszko J; Swinkels DW; Wetzels JF; Macdougall IC
Nephrol Dial Transplant; 2012 Oct; 27(10):3923-9. PubMed ID: 22815544
[TBL] [Abstract][Full Text] [Related]
3. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients.
Zaritsky J; Young B; Gales B; Wang HJ; Rastogi A; Westerman M; Nemeth E; Ganz T; Salusky IB
Clin J Am Soc Nephrol; 2010 Jun; 5(6):1010-4. PubMed ID: 20299375
[TBL] [Abstract][Full Text] [Related]
4. HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients.
Valenti L; Girelli D; Valenti GF; Castagna A; Como G; Campostrini N; Rametta R; Dongiovanni P; Messa P; Fargion S
Clin J Am Soc Nephrol; 2009 Aug; 4(8):1331-7. PubMed ID: 19541813
[TBL] [Abstract][Full Text] [Related]
5. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents.
van der Weerd NC; Grooteman MP; Bots ML; van den Dorpel MA; den Hoedt CH; Mazairac AH; Nubé MJ; Penne EL; Gaillard CA; Wetzels JF; Wiegerinck ET; Swinkels DW; Blankestijn PJ; Ter Wee PM;
PLoS One; 2012; 7(7):e39783. PubMed ID: 22808058
[TBL] [Abstract][Full Text] [Related]
6. Hepcidin--a potential novel biomarker for iron status in chronic kidney disease.
Zaritsky J; Young B; Wang HJ; Westerman M; Olbina G; Nemeth E; Ganz T; Rivera S; Nissenson AR; Salusky IB
Clin J Am Soc Nephrol; 2009 Jun; 4(6):1051-6. PubMed ID: 19406957
[TBL] [Abstract][Full Text] [Related]
7. The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis.
Pelusi S; Girelli D; Rametta R; Campostrini N; Alfieri C; Traglia M; Dongiovanni P; Como G; Toniolo D; Camaschella C; Messa P; Fargion S; Valenti L
BMC Nephrol; 2013 Feb; 14():48. PubMed ID: 23433094
[TBL] [Abstract][Full Text] [Related]
8. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
[TBL] [Abstract][Full Text] [Related]
9. Serum hepcidin in haemodialysis patients: associations with iron status and microinflammation.
Xu Y; Ding XQ; Zou JZ; Liu ZH; Jiang SH; Chen YM
J Int Med Res; 2011; 39(5):1961-7. PubMed ID: 22118000
[TBL] [Abstract][Full Text] [Related]
10. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.
Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S
Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412
[TBL] [Abstract][Full Text] [Related]
11. Is hepcidin-25 a clinically relevant parameter for the iron status in hemodialysis patients?
Brătescu LO; Bârsan L; Munteanu D; Stancu S; Mircescu G
J Ren Nutr; 2010 Sep; 20(5 Suppl):S77-83. PubMed ID: 20797577
[TBL] [Abstract][Full Text] [Related]
12. Reproducibility of and correspondence among different hepcidin forms in blood and urine and their relationships to iron status in healthy, male Guatemalan volunteers observed over 9 weeks.
Schuemann K; Solomons NW; Laarakkers CM; Romero-Abal ME; Kroll S; Weiss G; Swinkels DW
Ann Nutr Metab; 2011; 58(2):158-66. PubMed ID: 21654163
[TBL] [Abstract][Full Text] [Related]
13. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study.
Uehata T; Tomosugi N; Shoji T; Sakaguchi Y; Suzuki A; Kaneko T; Okada N; Yamamoto R; Nagasawa Y; Kato K; Isaka Y; Rakugi H; Tsubakihara Y
Nephrol Dial Transplant; 2012 Mar; 27(3):1076-83. PubMed ID: 21799206
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow iron distribution, hepcidin, and ferroportin expression in renal anemia.
Bârsan L; Stanciu A; Stancu S; Căpuşă C; Brătescu L; Mandache E; Radu E; Mircescu G
Hematology; 2015 Oct; 20(9):543-52. PubMed ID: 25745821
[TBL] [Abstract][Full Text] [Related]
15. Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease.
Ueda N; Takasawa K
Nutrients; 2018 Aug; 10(9):. PubMed ID: 30150549
[TBL] [Abstract][Full Text] [Related]
16. Variability of ferritin measurements in chronic kidney disease; implications for iron management.
Ford BA; Coyne DW; Eby CS; Scott MG
Kidney Int; 2009 Jan; 75(1):104-10. PubMed ID: 18843257
[TBL] [Abstract][Full Text] [Related]
17. Association between hepcidin, haemoglobin level and iron status in stage 4 chronic kidney disease patients with anaemia.
Mogadam RA; Nemati A; Amani F; Ghorbanihaghjo A; Argani H; Bashardoust B
J Pak Med Assoc; 2015 Apr; 65(4):354-7. PubMed ID: 25976565
[TBL] [Abstract][Full Text] [Related]
18. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients.
Kato A; Tsuji T; Luo J; Sakao Y; Yasuda H; Hishida A
Am J Nephrol; 2008; 28(1):115-21. PubMed ID: 17943020
[TBL] [Abstract][Full Text] [Related]
19. Hepcidin: clinical utility as a diagnostic tool and therapeutic target.
Coyne DW
Kidney Int; 2011 Aug; 80(3):240-4. PubMed ID: 21677632
[TBL] [Abstract][Full Text] [Related]
20. Serum hepcidin-25 levels predict the progression of renal anemia in patients with non-dialysis chronic kidney disease.
Niihata K; Tomosugi N; Uehata T; Shoji T; Mitsumoto K; Shimizu M; Kawabata H; Sakaguchi Y; Suzuki A; Hayashi T; Okada N; Isaka Y; Rakugi H; Tsubakihara Y
Nephrol Dial Transplant; 2012 Dec; 27(12):4378-85; discussion 4384-5. PubMed ID: 22833619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]